Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test speeds therapeutic decision making for adults with acute myeloid leukemia, or AML. The standalone assay yields faster results than next generation sequencing.

(00:32)
 Would you provide a brief background of yourself?

(01:42)
 Could you give an overview of the IDHQ test?

(02:25)
 Is there anything more you'd like to touch on about the droplet digital PCR approach and high sensitivity?

(03:09)
 Why are IDH1 and IDH2 important in disease diagnosis, prognosis, or therapeutic management?

(05:00)
 Is there anything else you'd like to say about this particular assay?

(06:56)
 Would you describe the specific group of patients where testing is recommended?